Genvoya

treatment experienced, Treatment Naive, HIV
Treatment
2 FDA approvals
20 Active Studies for Genvoya

What is Genvoya

ElvitegravirThe Generic name of this drug
Treatment SummaryElvitegravir is a medication used to treat HIV-1 infections in adults who have already tried other antiretroviral treatments. It works by stopping the virus from replicating and spreading. Elvitegravir must be taken in combination with other medications, including an HIV protease inhibitor, ritonavir, and another antiretroviral drug. It was first licensed in 2008 and approved by the FDA in 2012. In 2014, the single pill form of elvitegravir was approved.
Stribildis the brand name
image of different drug pills on a surface
Genvoya Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Stribild
Elvitegravir
2012
10

Approved as Treatment by the FDA

Elvitegravir, also known as Stribild, is approved by the FDA for 2 uses which include treatment experienced and HIV .
treatment experienced
HIV

Effectiveness

How Genvoya works in the bodyElvitegravir is an anti-HIV drug that stops the virus from replicating. It does this by blocking the enzyme called integrase, which is needed for HIV-1 to spread. Elvitegravir does not affect the host's own topoisomerases, which are enzymes involved in DNA regulation.

When to interrupt dosage

The proposed measure of Genvoya is contingent upon the perceived condition, including treatment experienced, Treatment Naive and HIV (Human Immunodeficiency Virus). The amount of dosage relies upon the technique of delivery (e.g. Tablet, film coated or Tablet) delineated in the table hereunder.
Condition
Dosage
Administration
Treatment Naive
150.0 mg, , 85.0 mg
, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
treatment experienced
150.0 mg, , 85.0 mg
, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
HIV
150.0 mg, , 85.0 mg
, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral

Warnings

Genvoya Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Genvoya.
Common Genvoya Drug Interactions
Drug Name
Risk Level
Description
1,2-Benzodiazepine
Major
The metabolism of 1,2-Benzodiazepine can be decreased when combined with Elvitegravir.
3,5-diiodothyropropionic acid
Major
The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Elvitegravir.
5-androstenedione
Major
The metabolism of 5-androstenedione can be decreased when combined with Elvitegravir.
6-O-benzylguanine
Major
The metabolism of 6-O-benzylguanine can be decreased when combined with Elvitegravir.
7-ethyl-10-hydroxycamptothecin
Major
The metabolism of 7-ethyl-10-hydroxycamptothecin can be decreased when combined with Elvitegravir.
Genvoya Toxicity & Overdose RiskTaking elvitegravir may lead to nausea, vomiting, diarrhea, abdominal pain, indigestion, fatigue, insomnia, rash, depression, and suicidal thoughts or attempts. These side effects are not very common and occur in fewer than 2% of patients.
image of a doctor in a lab doing drug, clinical research

Genvoya Novel Uses: Which Conditions Have a Clinical Trial Featuring Genvoya?

43 active clinical trials are assessing the potential of Genvoya in managing HIV (Human Immunodeficiency Virus) in both Treatment Naive and Treatment Experienced Patients.
Condition
Clinical Trials
Trial Phases
treatment experienced
0 Actively Recruiting
HIV
39 Actively Recruiting
Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4
Treatment Naive
0 Actively Recruiting

Genvoya Reviews: What are patients saying about Genvoya?

5Patient Review
5/21/2017
Genvoya for HIV
I was diagnosed in April 2017 and have been amazed by the progress of my treatment.
5Patient Review
10/18/2016
Genvoya for HIV
This treatment is very simple, just one pill a day. I did experience some dizziness, but it was nothing compared to other drugs I've been prescribed.
5Patient Review
12/22/2016
Genvoya for HIV
I'm really pleased with genvoya. I started taking it on 8/1/2016 and haven't had a single side effect. In fact, not only did it get rid of a rash I had on my leg, but it did so within a month.
5Patient Review
4/28/2017
Genvoya for HIV
I'm pregnant and so far this medication has had zero negative side effects that I can tell.
5Patient Review
12/30/2017
Genvoya for HIV
I appreciate that I only have to take this medication once per day, and that there are no side effects. I've been on it for over two years now, and it has helped me immensely.
5Patient Review
7/7/2016
Genvoya for HIV
5Patient Review
8/20/2016
Genvoya for HIV
4.7Patient Review
10/10/2017
Genvoya for HIV
I was struggling to sleep, but this treatment really helped me.
4.7Patient Review
7/16/2016
Genvoya for HIV
3.7Patient Review
5/31/2018
Genvoya for HIV
I switched to this treatment a month ago and feel much healthier now. I also take an antifungal daily because of spinal meningitis, but my doctor is the best and he saved my life. Recovery was long, but it was worth it in the end.
3.7Patient Review
3/11/2019
Genvoya for HIV
I just took my first pill an hour and a half ago. I'm feeling a little tingling in my tongue and cheeks got red, sort of like when someone rubs them. I don't know yet how effective this pill is going to be.
3Patient Review
3/17/2019
Genvoya for Prevention of HIV Infection after Exposure
I feel like I can't get any good advice on which treatments will work best for me. I was on an old HIV treatment that had been working well for me for 20 years, but the drugs became temporarily unavailable. I was then advised to switch to Genvoya, and started having all kinds of bothersome side effects: fat distribution in my midsection, dryness in my mouth, wake up choking due to lack of moisture, difficulty sleeping.
1Patient Review
6/15/2017
Genvoya for HIV
I was diagnosed with HIV in 2014 and have been taking Genvoya for 1.5 years now. I haven't experienced any side effects that I know of, and I'm generally satisfied with the medication.
1Patient Review
6/21/2017
Genvoya for HIV
I developed a horrible rash and inflammation after using this treatment.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about genvoya

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can you drink alcohol while taking Genvoya?

"Most people can drink alcohol while taking Genvoya without any interactions."

Answered by AI

Is Genvoya the same as Biktarvy?

"Genvoya and Biktarvy are both antiretrovirals that contain elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. Biktarvy also contains bictegravir."

Answered by AI

Does Genvoya make you undetectable?

"In a study of people with HIV-1, those who switched to taking GENVOYA® were 93% more likely to still have an undetectable viral load after two years of treatment, as compared to those who stayed on their current treatment."

Answered by AI

What is Genvoya used to treat?

"Genvoya is a once-daily pill for treating HIV that combines four drugs: 150mg elvitegravir, 200mg emtricitabine, 10mg tenofovir alafenamide, and 150mg cobicistat. The green film-coated tablet bears the markings "GSI" on one side and "510" on the other."

Answered by AI

What are the side effects of Genvoya?

"Some common symptoms of HIV include nausea, diarrhea, fatigue, headaches, and changes in body fat distribution."

Answered by AI

Clinical Trials for Genvoya

Image of UCSF Zuckerberg San Francisco General Hospital in San Francisco, United States.

MucoCept-CVN for HIV Prevention

18 - 45
Female
San Francisco, CA
MucoCept-CVN uses a Lactobacillus strain native to the human vagina that is modified into a live biotherapeutic product (LBP) that continuously expresses a potent anti-HIV drug. If research shows that MucoCept-CVN is safe and effective, it could become a self-renewing, female-initiated prevention product for women that promotes vaginal health and provides protection from HIV. The goal of this first-in-human Phase 1 dose-ranging, randomized, placebo-controlled study of MucoCept-CVN is to collect data on safety, colonization, changes to the vaginal microbiota and clearance of the strain with antibiotics. Twelve healthy women will be enrolled and take either one or three doses of MucoCept-CVN or placebo, and a week later will receive antibiotics to clear the Lactobacillus strain. If research shows that MucoCept-CVN is safe and effective, it could become a self-renewing, long-acting, female-initiated prevention product for women that promotes vaginal health and provides protection from HIV.
Phase 1
Waitlist Available
UCSF Zuckerberg San Francisco General HospitalCraig Cohen, MD, MPHOsel, Inc.
Have you considered Genvoya clinical trials? We made a collection of clinical trials featuring Genvoya, we think they might fit your search criteria.Go to Trials
Image of Massachusetts General Hospital in Boston, United States.

SGLT2 Inhibitors for Metabolic Diseases

45 - 75
Female
Boston, MA
Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed. We are conducting a study randomizing women with HIV and either diabetes, chronic kidney disease, or both to health education alone or to health education plus referral to see either an Endocrinologist or a Nephrologist in a subspecialty clinic for consideration of treatment with medication in a class known as sodium glucose transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors are clinically approved for use in patients with diabetes or chronic kidney disease but have been shown to be underutilized in people with HIV. One of our key analytic aims will be to test if SGLT2 inhibitor therapy results in improved blood flow through the large and small coronary arteries among women with HIV and either diabetes, chronic kidney disease, or both but who have no history of myocardial infarction. A second aim will be to test if subspecialty clinic referral (with or without SGLT2 inhibitor therapy prescription) results in improved blood flow through the large and small coronary arteries among the same group.
Phase 2
Recruiting
Massachusetts General HospitalMarkella V Zanni, MD
Have you considered Genvoya clinical trials? We made a collection of clinical trials featuring Genvoya, we think they might fit your search criteria.Go to Trials
Image of Mills Clinical Research in West Hollywood, United States.

GS-1720 + GS-4182 for HIV

18+
All Sexes
West Hollywood, CA
The goal of this clinical study is to learn more about the experimental drugs GS-1720 (an oral, long-acting integrase strand transfer inhibitor (INSTI)) and GS-4182 (a prodrug of Lenacapavir (LEN)); to compare the combination of GS-1720 and GS-4182 with the current standard-of-care treatment bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (Biktarvy), to see if the combination of GS-1720 and GS-4182 is safe and if it works for treating human immunodeficiency virus type 1 (HIV-1) infection in treatment-naive people with HIV-1 (PWH). This study has two phases: Phase 2 and Phase 3. The primary objectives of this study are: Phase 2: To evaluate the efficacy of oral weekly GS-1720 coadministered with GS-4182 versus continuing Biktarvy (BVY) in treatment-naive PWH at Week 24. Phase 3: To evaluate the efficacy of oral weekly GS-1720/GS-4182 fixed-dose combination (FDC) tablet regimen versus continuing BVY in treatment-naive PWH at Week 48.
Phase 2 & 3
Waitlist Available
Mills Clinical Research (+25 Sites)Gilead Study DirectorGilead Sciences
Image of Saskatchewan Health Authority in Regina, Canada.

DOVATO for HIV

18+
All Sexes
Regina, Canada
The goal of this clinical trial is to determine the efficacy of Dolutegravir/Lamivudine (DTG/3TC), or "Dovato", in virally-suppressed (HIV-1 RNA \< 200 copies/mL) individuals receiving opioid agonist therapy such as methadone, buprenorphine, slow-release morphine, after switching from their current suppressive antiretroviral therapy (ART). The main questions this trial seeks to answer are: 1. whether people living with HIV-1 (PLWH) on opioid agonist therapy (OAT) remain virally suppressed after switching to DTG/3TC from their current suppressive ART 48 weeks post-switch; 2. the number and type of adverse events (AEs) and serious adverse events (SAEs) attributable to DTG/3TC as documented per standard process at each study visit, and any discontinuations of DTG/3TC due to AEs and SAEs as determined by the study investigator; 3. the number of dosing changes in OAT attributable to DTG/3TC as determined by the study investigator and documented as per standard progress at each study visit; 4. the number of persons with any recreational or non-prescribed substances in their urine drug screens who remain virally suppressed (HIV-1 RNA \< 200 copies/mL) at 48 weeks post-switch from current suppressive ART to DTG/3TC; 5. any change from baseline values (i.e., day 0) to 48 weeks post-switch from current suppressive ART to DTG/3TC of serum creatinine and non-fasting lipid parameters; 6. any change from baseline value (i.e., day 0) to 48 weeks post-switch from current suppressive ART to DTG/3TC in HIV Treatment Satisfaction Questionnaire (Status) (HIVTSQs) scores; 7. the number of persons who remain virally suppressed (HIV RNA \< 200 copies/mL) at 48 weeks post-switch from current suppressive ART to DTG/3TC in conjunction with differing levels of adherence to DTG/3TC, and; 8. the number of persons who experience symptoms of opioid withdrawal or overdose per standardized survey or by self-report (e.g., overdose events) During the course of the study, participants will complete: * A set of questionnaires * Blood draws * A review of adverse events and concomitant medications * ECG scans at screening and 48 weeks * Urine drug screening * Physical exams * Review of alcohol consumption
Phase 4
Waitlist Available
Saskatchewan Health AuthorityViiV Healthcare
Image of University of Colorado - Anschutz Medical Campus in Aurora, United States.

Tesamorelin + Exercise for HIV

50 - 80
All Sexes
Aurora, CO
People with HIV experience earlier impairments in physical function compared to people in the general population. They also exhibit an earlier presentation and more rapid development of frailty, a multisystemic syndrome of aging characterized by reduced activity, fatigue, slowness, weakness, and weight loss. While exercise can improve physical function in people with HIV, it is less effective in doing so than in the general population and is difficult to sustain in the long-term. The goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise. Tesamorelin is a growth hormone-releasing hormone analogue that is FDA-approved to treat abdominal fat accumulation in people with HIV. While tesamorelin has also been shown to increase muscle mass and improve measures of muscle health, its effects on physical performance and muscle strength have not yet been evaluated. During a 24-week intervention phase, half of participants will be randomly assigned to receive tesamorelin and half of participants will be randomly assigned to receive placebo (a look-alike substance that contains no drug). All participants also will engage in a home-based exercise intervention supervised by an exercise coach. During a subsequent 24-week extension phase, individuals will be monitored off study drug and supervised exercise, and be encouraged to continue to exercise independently. The investigators will investigate effects of tesamorelin on physical function, muscle mass and quality, quality of life, and exercise adherence and self-efficacy. They also will evaluate whether effects of tesamorelin are maintained following treatment cessation. This study may identify an important strategy to improve how individuals aging with HIV function and feel with potential applications to other patient populations.
Phase 2
Recruiting
University of Colorado - Anschutz Medical Campus (+1 Sites)Lindsay T. Fourman, MD
Have you considered Genvoya clinical trials? We made a collection of clinical trials featuring Genvoya, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security